These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29124793)

  • 1. Evidence for allosteric effects on p53 oligomerization induced by phosphorylation.
    Muller P; Chan JM; Simoncik O; Fojta M; Lane DP; Hupp T; Vojtesek B
    Protein Sci; 2018 Feb; 27(2):523-530. PubMed ID: 29124793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding.
    Cesková P; Chichger H; Wallace M; Vojtesek B; Hupp TR
    J Mol Biol; 2006 Mar; 357(2):442-56. PubMed ID: 16438982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
    Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
    Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group.
    Hansen S; Hupp TR; Lane DP
    J Biol Chem; 1996 Feb; 271(7):3917-24. PubMed ID: 8632013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53.
    Fraser JA; Madhumalar A; Blackburn E; Bramham J; Walkinshaw MD; Verma C; Hupp TR
    J Biol Chem; 2010 Nov; 285(48):37773-86. PubMed ID: 20847049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain.
    D'Abramo M; Bešker N; Desideri A; Levine AJ; Melino G; Chillemi G
    Oncogene; 2016 Jun; 35(25):3272-81. PubMed ID: 26477317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
    Lubin DJ; Butler JS; Loh SN
    J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein.
    Cohen PA; Hupp TR; Lane DP; Daniels DA
    FEBS Lett; 1999 Dec; 463(1-2):179-84. PubMed ID: 10601663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric activation of latent p53 tetramers.
    Hupp TR; Lane DP
    Curr Biol; 1994 Oct; 4(10):865-75. PubMed ID: 7850419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PAb240+ conformation of wild type p53 binds DNA.
    McLure KG; Lee PW
    Oncogene; 1996 Sep; 13(6):1297-303. PubMed ID: 8808704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'regulatory' beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation.
    Bjørling-Poulsen M; Siehler S; Wiesmüller L; Meek D; Niefind K; Issinger OG
    Oncogene; 2005 Sep; 24(40):6194-200. PubMed ID: 15940255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended string binding mode of the phosphorylated transactivation domain of tumor suppressor p53.
    Okuda M; Nishimura Y
    J Am Chem Soc; 2014 Oct; 136(40):14143-52. PubMed ID: 25216154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain.
    Krois AS; Dyson HJ; Wright PE
    Proc Natl Acad Sci U S A; 2018 Nov; 115(48):E11302-E11310. PubMed ID: 30420502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttranslational regulation of p53 tumor suppressor protein function.
    Maxwell SA; Roth JA
    Crit Rev Oncog; 1994; 5(1):23-57. PubMed ID: 7948107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating Conformational Dynamics and Allostery in the p53 DNA-Binding Domain Using Molecular Simulations.
    Papaleo E
    Methods Mol Biol; 2021; 2253():221-244. PubMed ID: 33315226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Domain-domain interactions in full-length p53 and a specific DNA complex probed by methyl NMR spectroscopy.
    Bista M; Freund SM; Fersht AR
    Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15752-6. PubMed ID: 22972749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
    Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
    Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases.
    Hupp TR; Lane DP
    Cold Spring Harb Symp Quant Biol; 1994; 59():195-206. PubMed ID: 7587070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phosphorylation-dependent switch in the disordered p53 transactivation domain regulates DNA binding.
    Sun X; Dyson HJ; Wright PE
    Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sliding of p53 along DNA can be modulated by its oligomeric state and by cross-talks between its constituent domains.
    Khazanov N; Levy Y
    J Mol Biol; 2011 Apr; 408(2):335-55. PubMed ID: 21338609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.